INTRODUCTION
World Health Organization (WHO) Grade II and III gliomas are tumors of the central nervous system (CNS) defined as lower-grade gliomas (LGGs) upon the clinical behavior and molecular stratification [1] [2] [3] .
The updated WHO classification 1 considers both histologic and molecular parameters as crucial for an integrated diagnosis. However, the coexistence of areas with different histological and biological characteristics in the same tumor can impair the possibility to reach a correct diagnosis.
Conventional MRI is the standard modality for the pre-operative characterization of a primary brain tumor 4,5 , but
LGGs often show absence of contrast enhancement in the early stages of progression, which can lead to an underestimation of tumor grading 4, 6 .
Positron emission tomography (PET) with radiolabelled amino-acids, like L-methyl-C11-methionine (11C-METH), has been proven to be a valuable tool for the in vivo characterization of brain tumors. It has been shown that 11C-METH PET can differentiate gliomas 7-11 , it can provide prognostic information prior to surgery [12] [13] [14] [15] [16] , it can be used for
METHODS

Patients' population
A series of 96 patients (51 males, 45 females; age 44.1±13.7 years) affected by LGGs (i.e.
grade II and III), who underwent a craniotomy for tumor resection from March 2012 to January 2015, was analyzed in this observational cohort study (NCT02518061). All patients had 11C-METH PET performed within 30 days before surgery, adequate tumor specimen following surgery and fully available clinical data including complete follow-up.
Demographic profile and clinical-radiological features are reported in [ Table 1 
11C-METH PET imaging
Before surgery, all patients performed 11C-METH PET. The radiopharmaceutical, carrierfree L-(methyl-11C)-methionine, was synthesized on-site using a General Electric TracerLab
FXc synthesis module with the method previously described 12 . A total amount of 300-500MBq, was administered in patients who had been fasting for at least 4 hours. Images were acquired 15 minutes later on a PET/CT tomograph, either a Biograph 6 LSO scanner (Siemens Medical Systems, Erlangen, Germany) or a Discovery 690 GE scanner (General Electric Healthcare, Waukesha, WI). CT attenuation-corrected 3D images were acquired for 10min from the scalp to vertebra C3 level and images were subsequently reconstructed using an iterative reconstruction algorithm (OSEM) and displayed on GE Adw4.6 Workstation.
Images were reconstructed and acquired in order to minimize differences in semi-quantitative evaluations related to the use of two different scanners. 
Statistical analyses
An analysis of variance (ANOVA) was employed to explore the relationship among the PET metrics, as measured by semiquantitative parameters, and clinico-radiological features.
Differences between rates were compared by the Chi square analysis. T-test was used to investigate differences between scanners (Siemens versus GE) for semiquantitative parameters.
To investigate the relationship among metabolic metrics and the 3 molecular subgroups, the PET metrics were analyzed with ANOVA on the natural log of the dependent variable (the Ftest) and with a non-parametric Kruskal-Wallis test, due to distributional concerns. LGGs. [ Figure 1A -B] reports representative examples.
The MRI lesion volume was correlated only to MTB (F(1.93)=9.9, p=0.002) but not SUVmax or SUVratio: however, the correlation between MRI volume and MTB was modest (r 2 =0.13) [ Figure S2 ].
Accuracy, sensitivity and specificity of lesion characterization by PET and MRI
Accuracy, sensitivity and specificity of the three PET measurements in discriminating between grade II and III was evaluated. Results showed an overall good accuracy, especially concerning specificity. Grade was statistically predicted by SUVmax (p<0.001), SUVratio (p=0.002) and also MTB (p<0.001). Optimal cut-off values were 2.7, 2.0 and 14.9 for SUVmax, SUVratio and MTB, respectively [ Table 3 ].
To assess whether the combination of PET parameters and MRI features, namely the presence of contrast enhancement, is superior in the diagnostic accuracy to discriminate between grade II and III a further analysis was performed. In particular, the likelihood of a grade III lesion is higher when contrast enhancement co-exists with higher PET semiquantitative values; an overall gain in accuracy, sensitivity and specificity is observed, as reported in [ Table 4 ] compared to MR or PET alone.
PET semi-quantitative metrics and molecular features
The relationships between metabolic parameters and molecular features was explored, constraining the analysis to newly diagnosed lesions. 
DISCUSSION
LGGs Although In this study, we also found a significant association between IDH status and PET parameters, as IDH-1/2 wild-type lesions displayed a higher metabolic activity than IDH-1/2 mutated LGGs in terms of SUVmax and SUVratio, while 1p19q codeleted lesions had a lower SUVratio. The latter finding, i.e. the relationship between the 1p19q loss of heterozygosity (LOH) and PET metrics can appear controversial when compared to earlier studies 15 , where LGGs with 1p19q codeletion displayed higher uptake of PET tracers.
However, a more recent study found that 11C-METH-PET metrics were significantly higher in oligodendroglial lesions without 1p/19q deletion especially when the tumor to normal brain ratio was analyzed 39 , as in this study. This discrepancy could be explained by several factors, such as heterogeneity of different clinical cohorts and different percentages of true astrocytic and oligodendroglial lesions 41 . In addition, it could be argued that tumors without 1p/19q deletion are less likely to have IDH1 mutation and this can lead to a more active metabolism than those with the deletions 2, 41 .
When we analyzed the 3 molecular subgroups we restricted the analysis to newly diagnosed lesions. IDH-1/2 wild-type lesions displayed a higher metabolic activity than IDHmutated/1p19 codeleted lesions and IDH-mutated/1p19q-not-codeleted lesions, as measured with SUVmax and SUVratio; however, the difference did not reach statistically significance.
This could be due to either the small number of patients in each subgroup or the high relative fraction of IDH-wild type lesions. Further studies are thus needed to prove whether this interesting preliminary finding can be confirmed with a greater sample size and, hopefully a prospective design 42 . where the new WHO brain tumor classification can be considered ab initio.
Some attention must be paid to acquisition protocols and reconstruction algorithms, particularly in the context of multiple scanner types or in multicentric settings, since the inter and intra-center comparability of PET data should be based on harmonized criteria. In addition, when a robust correlation between imaging data and other patient's pathological features is demonstrated, quantitative diagnostic findings could guide the choice of the site of tissue sampling, as it was done in the current study, where samples from hypermetabolic areas were sent separately for the histopathological diagnosis. This approach can reduce the errors in the histopathological evaluation, that are due to both sampling errors and interobserver variability 43 . Values are reported as percentages. 
CONCLUSION
